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DA TEVAR approach in this situation may have eliminated
the risk for rupture. It is unclear, however, whether this
benefit of TEVAR outweighs its reported risk of paraplegia
or retrograde dissection, neither of which was observed with
the percutaneous fenestration approach in our series.
Study Limitations
Limitations of this study include its retrospective nature
and lack of comparison group (eg, open repair, TEVAR,
or open fenestration groups). In addition, although this study
describes outcomes for treatment of one of the largest series
of patients with B-MP, the sample size is relatively small. Fi-
nally, although the follow-up for the primary end point of
mortality is complete, there is incomplete imaging follow-
up (21% without postdischarge imaging).
Our current approach at the University of Michigan is
based on risk stratification to determine the most suitable op-
tion. We elect to perform fenestration and stenting for those
patients with small total aortic diameters presenting with
malperfusion. If the patient is young but presents with an
aortic diameter greater than 5 cm, we will initially attempt
to resolve the malperfusion with fenestration and stenting
and then subsequently treat the aneurysm with an open ap-
proach within several weeks of presentation. TEVAR is re-
served for those presenting with malperfusion who are older
(70 years) and have total aortic diameters greater than 4.5
to 5 cm or those presenting with the complication of rupture
in association with malperfusion.
CONCLUSIONS
We have described the late results of a percutaneous-
based approach for the treatment of peripheral ischemic
complications resulting from B-AD. In contrast with data re-
ported from open repair, these long-term data may serve as
a more suitable comparison against which to evaluate
TEVAR as a primary therapeutic modality for this lethal
disease.
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Discussion
Eric Roselli, MD (Cleveland, Ohio). Congratulations on a fine
presentation and an outstanding experience. Dr Patel and I did some
of our endovascular training together under the leadership of Roy
Greenberg, who apologizes for not being here today, but he and I
reviewed the article together and compiled the following questions
and observations.
Dr Patel and colleagues at the University of Michigan have pro-
vided us with a relatively large amount of long-term data regarding
a technique used to treat malperfusion syndrome after acute distal
dissection. Dr Williams and his counterparts have long been con-
sidered the pioneers of these complex interventional techniques,
and their expertise in aortic flap fenestrations is likely unparalleled.
However, several fundamental questions are raised by both the im-
plementation of such a treatment strategy and the extended follow-
up data you have provided.
Would you please clarify your patient population? Malperfusion
is really a clinical syndrome rather than a radiographic diagnosis,
yet in your series you included patients with a clinical syndrome
and evidence of true lumen collapse by computed axial tomography
scan. Can you segregate your results to provide us with the number
of patients treated solely on the basis of radiographic evidence of
true lumen collapse or ischemia versus those with clinical evidence
of this complication along with their respective outcomes?
Dr Patel. You are absolutely correct in that there is a difference
between radiographic findings and presentation with a syndrome of
end-organ dysfunction. We completely agree with that. The latter,
the syndrome of end-organ dysfunction, results from prolonged is-
chemia, and at our center, because of the availability of these inter-
ventional techniques, we have taken an aggressive stance in
studying patients who present with angiographic or CT findings
to prevent the subsequent development of end-organ failure from
prolonged ischemia.rgery c August 2009
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statistical difference in outcomes, and this was likely secondary
to the small sample size in the group that was studied only for an-
giographic findings.
Dr Roselli. Very good. The 2 therapies principally used to
treat malperfusion after acute aortic dissection remain endovascu-
lar grafting and aortic flap fenestration, as you clearly described to
us in the beginning of your talk. We have used both techniques;
however, the pendulum has recently swung strongly in the direc-
tion of stent-graft therapy. Although some of this may relate to
the relative simplicity of endovascular grafting over the flap fen-
estration, I believe that much of this has to do with the treatment
objectives.
The rationale for stent-graft therapy is that covering the primary
fenestration markedly decreases false lumen inflow, allowing the
false lumen to passively decompress. We have found that perfusion
of the mesenteric vessels, lower extremities, and renal branches are
almost always restored via this technique once we reestablish true
lumen flow, and it is exceedingly rare that we have to stent the
branch vessels. In addition, the use of these stent grafts promotes
false lumen thrombosis and in the region of the treatment may pro-
mote aortic remodeling. In contrast, aortic flap fenestration allows
flow through a widened fenestration and equalization through the 2
lumens, which may increase the likelihood of static compression, at
least in our experience.
Howmany arteries in your series required flap fenestration in ad-
dition to branch stenting, and were the outcomes different in those
patients?
Dr Patel. Eric, again, you are correct in that by excluding false
lumen flow with TEVAR, you may resolve the associated static ob-
struction by decompressing the false lumen. I at present do not have
the number of arteries that required branch vessel stents in our co-
hort, but I can tell you that in our analysis, we did find that 43 of the
69 patients required branch vessel stents. We do agree that the point
you raise is an important one, and we will have to construct that
analysis to allow for a suitable comparison of both TEVAR and
this approach.
Dr Roselli. I have one last question. It was a little disconcerting
to us that in this large landmark series only 15 of the 69 patients
were available at 2 years for, presumably, imaging studies, that
is, in your second analysis in which you looked at freedom from re-
operation and rupture. We share your view that once a patient has
a dissection, he/she should become your patient for life, and all of
the procedures that are performed should be done in the context of
anticipating a later repair. You described 5 early ruptures and 14 pa-
tients with late rupture or reoperation, for a rate of more than 20%.
Do you think that the rate of significant growth of these aortas was
even higher and that some of these patients were not deemed oper-
ative candidates? Also in this subgroup of patients, did you look to
see if there were any other factors such as an initial aortic diameter
of more than 4 cm or a false lumen diameter more than 22 mm, and
if so, should those patients have been treated with stent grafting in
addition to fenestration and branch grafting?
Dr Patel. You are correct in stating a major limitation of our re-
sults. I think the point that we would like to make is that when we
undertook this analysis, at the time when this procedure was really
started, there was no ability to provide thoracic endografting for pa-
tients with acute type B dissection. The goal of the therapy when itThe Journal of Thoracic and Cwas first started was to restore the branch vessel perfusion and per-
haps restore the survival curve toward that seen with uncomplicated
dissection.
You are absolutely right that the limitations of the article are
such that we do not have complete imaging follow-up in this co-
hort. What we did find when we accounted for all of this was that
the survival analysis suggested that the mean time to open repair or
rupture was 79 months. We did not specifically look at aortic or
false lumen diameters in this study. Whether the results we show
are good or not, I am not sure, but we do believe that they are better
than the results for open surgical series that have been reported and,
as well, medical therapy for type B dissection presenting with is-
chemia. We therefore believe that the report we have proposed
should be considered a better benchmark study for evaluation of
newer therapies, such as TEVAR.
At our institution, we wholeheartedly believe in the thoracic en-
dovascular approach in this setting, and I think there are certain ad-
vantages for TEVAR that we suspect are likely not present with the
fenestration and stenting approach. However, as we move forward
and more and more groups describe outcomes with endovascular
repair for ischemic type B dissections, I think rather than comparing
them with open repair, which has a known dismal prognosis, this
report would probably be a more suitable comparison.
D. Craig Miller, MD (Stanford, Calif). Be careful what you
wish for, Dr Patel, because the data are already out there. I wasn’t
going to get up until I heard you say that you use these results as
a benchmark for thoracic aortic stent-grafting. I am sorry, but this
is very old flap fenestration and a true lumen stenting approach
can’t compete. We explored ‘‘fen-stent’’ for complications of acute
and chronic aortic dissection in the late 1980s and early 1990s but
abandoned it for the most part when we started thoracic aortic
stent-grafting in 1992, except when used as an adjunct after stent
grafting.
An article published in 1999 with our colleagues at Mie Univer-
sity, Japan, included only 29 patients, certainly not a big number,
but as Eric just said, let’s carefully define the substrate we are talk-
ing about. These were very sick people with complicated acute type
B dissections who were malperfused and basically dying in front of
us. Our initial goal was simply patient salvage. There were some
early deaths; we got caught, just like you have in Michigan, by try-
ing even though irreversible end-organ damage had already oc-
curred, or something Dr Shumway likened to ‘‘doing warm
autopsies.’’ We try to avoid this pitfall, but it is nearly impossible
to knowwho is salvageable and who is not with certainty. Now, just
including patients with Stanford complicated acute type B aortic
dissection, we have 16 who underwent emergency thoracic aortic
stent-grafting who have been followed for 5 years; follow-up com-
pleteness was 100%. After the initial 25þor –11% early mortality,
there were no additional deaths. The 5-year actuarial survival esti-
mate was 73þor –11% (Verhoye JP, Miller DC, Sze D, Dake MD,
Mitchell RS. Complicated acute type B aortic dissection: midterm
results of emergency endovascular stent-grafting. J Thorac
Cardiovasc Surg. 2008;136:424-30). Therefore, I submit this is
the first-generation stent-graft benchmark you were referring to
for comparison, not your results with ‘‘fen-stent.’’ Flap fenestration
and true lumen stenting for static obstruction are valuable adjuncts
after stent grafting but cannot compete as a primary first line of ther-
apy for acute aortic dissection today.ardiovascular Surgery c Volume 138, Number 2 307
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DSecond, we have to define what we are trying to do. In your con-
clusion slide you listed rupture and death, and you said both are
bad. Well, yes, death is usually pretty bad, but needing a late
open operation is not necessarily bad. Maybe that should be part
of our overall strategic goal, that is, do something quickly such
as a stent-graft to ameliorate the life-threatening lower-body mal-
perfusion, resuscitate the patients, and get them into better condi-
tion when an open thoracic or thoracoabdominal aortic operation
under more favorable conditions might proffer the optimal likeli-
hood of long-term survival. I don’t have any questions; I am just
issuing some words of caution.
Dr Patel. Just for the record, I will not compare myself with
you. But I do suggest that we agree that endovascular repair for
acute type B dissection is really here to stay, and we fully believe
in it. We have a different approach at Michigan. We suggest that
because of the unknown late results, we tend to perform thoracic
endografting in older patients. However, in younger patients, we
have been aggressive with fenestration and stenting. If they do re-
quire aorta repair for degeneration down the road, we do know308 The Journal of Thoracic and Cardiovascular Surfrom our series and others that elective open repair is associated
with acceptable early and late results. In essence what we are doing
with fenestration and stenting in younger patients is exactly what
you proposed, and that is converting a patient who is dying in front
of you into a more elective situation in which he/she is more sal-
vageable.
BruceW. Lytle,MD (Cleveland, Ohio). If I understand you cor-
rectly, however, today you would not choose to do this procedure.
Or if I misunderstood you and you would perform this procedure
rather than stenting, who would you do it for?
Dr Patel. We do still do this procedure. As I said, for patients
who are younger, we do not know the long-term results of TEVAR
in this setting. At our institution, if a younger patient presents with
acute type B dissection with malperfusion, then we will often re-
store the branch vessel perfusion with fenestration and stenting.
If the aorta subsequently degenerates, the patient will then often
receive open therapy. If the patient is older, then we are more
aggressive with performing an endograft approach to treat the mal-
perfusion syndrome.gery c August 2009
